BioLineRx Ltd. (BLRX) vs VistaGen Therapeutics, Inc. (VTGN)

BioLineRx Ltd. and VistaGen Therapeutics, Inc. are both Biotechnology companies. BioLineRx Ltd. and VistaGen Therapeutics, Inc. are of similar size ($12.7M and $12.6M). VistaGen Therapeutics, Inc. grew revenue faster over the last twelve months: 287.2% against −91.9%. BioLineRx Ltd. has the higher net margin (−502.1% vs −2,703.7%) and the lower return on invested capital (−74.3% vs 0.00%). Across the 17 metrics below, VistaGen Therapeutics, Inc. leads on 9 and BioLineRx Ltd. on 8.

Valuation

Metric BLRX VTGN Biotechnology median
P/E n/m n/m 7.88
P/S 8.14 4.64 11.47
P/B 0.68 0.47 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.28 0.74
EV/Sales 3.55 (7.84) 10.73
Earnings yield (66.27%) (614.81%) (28.84%)
Free cash flow yield (95.69%) (538.13%) (23.03%)

Profitability

Metric BLRX VTGN Biotechnology median
Gross margin 80.03% 100.00% 65.16%
Operating margin (874.28%) (2,785.69%) 0.00%
Net margin (502.08%) (2,703.72%) 0.00%
Free cash flow margin (776.29%) (2,490.88%) 0.00%
Return on equity (38.10%) (166.46%) (57.72%)
Return on assets (18.21%) (129.22%) (49.22%)
Return on invested capital (74.28%) 0.00% 0.00%

Growth

Metric BLRX VTGN Biotechnology median
Revenue growth (TTM) (91.93%) 287.15% 5.64%
EPS growth (last fiscal year) 93.72% (9.58%) —
Revenue growth, 5-year CAGR — 3.10% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BLRX VTGN Biotechnology median
Debt to equity 0.40 0.00 0.00
Current ratio 1.20 3.07 4.73
Net debt to EBITDA 1.22 0.63 0.96

Dividend

Metric BLRX VTGN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BLRX VTGN Biotechnology median
Market cap 12.55m 12.65m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack